Condition: T-cell Lymphoma · Sponsor: Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.
This description comes directly from the study's public registry record.
Zachary Epstein-Peterson, MD · 646-608-4176 · epsteinz@mskcc.org
Steven Horwitz, MD · 646-608-3725
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute (Data Collection Only) | Boston, Massachusetts, United States | Not Yet Recruiting |
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited protocol activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (All protocol activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited protocol activities) | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06756308